News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The VITA-FAST tokens have been met with overwhelming interest
The company is already marketing the 4 mg and 10 mg strengths
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Subscribe To Our Newsletter & Stay Updated
